Abstract
Background
Surgery for gastric cancer should be performed as soon as possible after diagnosis. However, sometimes the waiting time for surgery tends to be longer. The relation between the waiting time for surgery and survival in patients with gastric cancer remains to be fully investigated.
Methods
This retrospective, single-center cohort study evaluated patients with gastric cancer who underwent curative surgery from 2006 through 2012 at Kanagawa Cancer Center in Japan. Patients who received neoadjuvant chemotherapy were excluded. The waiting time for surgery was defined as the time between the first visit and surgery. We investigated whether the waiting time for surgery has a linear negative impact on outcomes by using a Cox regression model with clinical prognostic factors.
Results
In total, 801 patients were eligible. The median waiting time was 45 days (range 10–269 days). The restricted cubic spline regression curve showed that the adjusted time-specific hazard ratios of waiting times did not indicate a linear negative trend on survival between 20 and 100 days (p = 0.759). In the Cox model with a quartile of waiting times, waiting times in the 32–44-day group, 43–62-day group, and ≥63 day groups were not associated with poorer overall survival as compared with the ≤31 day group (HR: 1.01, 95% CI 0.63–1.60, p = 0.984, HR: 1.17, 95% CI 0.70–1.94, p = 0.550, HR: 1.06, 95% CI 0.60–1.88, p = 0.831, respectively).
Conclusions
There was no negative relation between the waiting time for surgery (within 100 days) and survival in patients with gastric cancer.
Similar content being viewed by others
References
Observatory TGC Cancer Today, World Health Organization (2019)
Association. JGc (2011) Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14:113–123
Health Do Cancer Reform Strategy, UK, Department of Health, 2007
Brenkman HJF, Visser E, van Rossum PSN et al (2017) Association between waiting time from diagnosis to treatment and survival in patients with curable gastric cancer: a population-based study in the Netherlands. Ann Surg Oncol 24:1761–1769
Ontario CC Target Wait Times for Cancer Surgery in Ontario, 2006
Sobin LHWC, Gospodarowicz M (2009) TNM classification of malignant tumors (UICC), 7th edn. Wiley, New York
Nakajima T (2002) Gastric cancer treatment guidelines in Japan. Gastric Cancer 5:1–5
Bleicher RJ, Ruth K, Sigurdson ER et al (2016) Time to surgery and breast cancer survival in the United States. JAMA Oncol 2:330–339
Coughlin S, Plourde M, Guidolin K et al (2015) Is it safe to wait? The effect of surgical wait time on survival in patients with non-small cell lung cancer. Can J Surg 58:414–418
Elit LM, O’Leary EM, Pond GR et al (2014) Impact of wait times on survival for women with uterine cancer. J Clin Oncol 32:27–33
Flemming JA, Nanji S, Wei X et al (2017) Association between the time to surgery and survival among patients with colon cancer: a population-based study. Eur J Surg Oncol 43:1447–1455
van Harten MC, Hoebers FJ, Kross KW et al (2015) Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol 51:272–278
Visser E, Leeftink AG, van Rossum PS et al (2016) Waiting time from diagnosis to treatment has no impact on survival in patients with esophageal cancer. Ann Surg Oncol 23:2679–2689
Neal RD, Tharmanathan P, France B et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112(Suppl 1):S92–107
Yun YH, Kim YA, Min YH et al (2012) The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. Ann Oncol 23:2731–2737
Tsukuma H, Oshima A, Narahara H et al (2000) Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut 47:618–621
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Koji Oba has following relevant financial activities outside the submitted work: Honoraria from Takeda Pharmaceutical Co., Ltd; Ono Pharmaceutical Co., Ltd; Eisai Co., Ltd; Chugai Pharmaceutical Co, Ltd.; Daiichi Sankyo Co., Ltd. Other authors declare that they have no conflict of interest.
Ethical statement
The study was reviewed and approved by the Institutional Review Boards of Kanagawa Cancer Center.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kumazu, Y., Oba, K., Hayashi, T. et al. Relationship Between the Waiting Times for Surgery and Survival in Patients with Gastric Cancer. World J Surg 44, 1209–1215 (2020). https://doi.org/10.1007/s00268-020-05367-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-020-05367-8